In the laboratory, Dr. Lane’s early work involved studies aimed at dissecting the normal immunoregulatory mechanisms that control the human immune response to specific antigen challenges. When the AIDS epidemic emerged, he became one of the first investigators to study immunopathogenic mechanisms of HIV disease, ultimately making seminal observations that helped establish the field of HIV immunopathogenesis.

Dr. Lane has used investigational therapeutic interventions to further the understanding of HIV pathogenesis. He pioneered the strategies of immunologically compatible bone marrow transplantation and the adoptive transfer of lymphocytes and has examined the roles of cytokines in treating patients with HIV infection.

Dr. Lane received his M.D. from the University of Michigan in 1976. He then completed an internship and residency at the University of Michigan Hospital, Ann Arbor. In 1979, Dr. Lane came to the National Institutes of Health as a clinical associate in the Laboratory of Immunoregulation (LIR). In 1985, he was appointed deputy clinical director of NIAID; in 1989, he became the chief of the Clinical and Molecular Retrovirology Section of LIR, a position he still holds. In 1991, Dr. Lane became clinical director of NIAID and, in 2006, became NIAID Deputy Director for Clinical Research and Special Projects. He is currently on the editorial boards of theJournal of Acquired Immune Deficiency Syndromes and The American Journal of Medicine.

Michael Sneller – Medical Officer
Hiromi Imamichi– Staff Scientist
Marta Catalfamo – Guest Researcher
Vishakha Thaker– Biologist
Mindy Smith – Biologist
Hui Chen – Visiting Fellow
Bruktawit Goshu – Post Bac IRTA
Tracey Zhai – Post Bac IRTA
Cecile Le Saout – Special Volunteer
Francesca Scrimieri - Special Volunteer
Steven Zeichner – Special Volunteer

Imamichi H, Lane HC. Regulatory T cells in HIV-1 infection: the good, the bad, and the ugly. J Infect Dis. 2012 May;205(10):1479-82.

Ledwaba L, Tavel JA, Khabo P, Maja P, Qin J, Sangweni P, Liu X, Follmann D, Metcalf JA, Orsega S, Baseler B, Neaton JD, Lane HC; Project Phidisa Biomarkers Team. Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. PLoS One. 2012;7(3):e24243.

Sneller MC, Kopp WC, Engelke KJ, Yovandich JL, Creekmore SP, Waldmann TA, Lane HC. IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood. Blood. 2011 Dec 22;118(26):6845-8.

Lane HC. Pathogenesis of HIV infection: total CD4+ T-cell pool, immune activation, and inflammation. Top HIV Med. 2010 Feb-Mar;18(1):2-6.

Visit PubMed for a complete publication listing.

Lane HC, Kovacs JA, Fauci AS, inventors; The United States of America as represented by the Department of Health and Human Services, assignee. Immunologic enhancement with intermittent interleukin-2 therapy. United States patent US 6,548,055. 15 Apr 2003.

Lane HC, Kovacs JA, Fauci AS, inventors; The United States of America as represented by the Department of Health and Human Services, assignee. Immunologic enhancement with intermittent interleukin-2 therapy. United States patent US 6,190,656. 20 Feb 2001.

Lane HC, Kovacs JA, Fauci AS, inventors; The United States of America as represented by the Department of Health and Human Services, assignee. Immunologic enhancement with intermittent interleukin-2 therapy. United States patent US 5,696,079. 9 Dec 1997.

Lane HC, Kovacs JA, inventors; The United States of America as represented by the Department of Health and Human Services, assignee. Immunologic enhancement with intermittent interleukin-2 therapy. United States patent US 5,419,900. 30 May 1995.